Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity

Vaccine

Volumn 27, Issue 46, 2009, Pages 6394-6398

  Gabitzsch, Elizabeth S ^a   Xu, Younong ^a   Yoshida, Lois H ^a   Balint, Joseph ^a   Amalfitano, Andrea ^b   Jones, Frank R ^a  

^a Etubics Corporation   (United States)

^b Michigan State University ^*  (United States)

Author keywords

Ad5 immunity; Adenovirus; HIV 1; Vaccine

Indexed keywords

AD5 [E1,E2B]GAG VACCINE; AD5 [E1,E2B]NEF VACCINE; AD5 [E1,E2B]POL VACCINE; ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN B; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; NEF PROTEIN; POL PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TRANSGENE; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; NEUTRALIZATION TESTS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SPLEEN; TRANSGENES; VACCINES, SYNTHETIC;

EID: 70350070724     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.028     Document Type: Article

References (26)

1. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189 (1999) 991-998
2. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 (1999) 857-860
3. Gómez-Román V.R., and Robert-Guroff M. Adenoviruses as vectors for HIV vaccines. AIDS Rev 5 (2003) 178-185
4. Robinson H.L. New hope for an AIDS vaccine. Nat Rev Immunol 2 (2002) 239-250
5. Gallichan W.S., and Rosenthal K.L. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 184 (1996) 1879-1890
6. Jooss K., Yang Y., Fisher K.J., and Wilson J.M. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 72 (1998) 4212-4223
7. Kirk C.J., and Mulé J.J. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 11 (2000) 797-806
8. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77 (2003) 6305-6313
9. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77 (2003) 799-803
10. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002) 331-335
11. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194 (2006) 1638-1649
12. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170 3 (2003) 1416-1422
13. Shiver J.W., and Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55 (2004) 355-372
14. Xiang Z., Gao G., Reyes-Sandoval A., Cohen C.J., Li Y., Bergelson J.M., et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76 (2002) 2667-2675
15. Amalfitano A., Hauser M.A., Hu H., Serra D., Begy C.R., and Chamberlain J.S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 72 (1998) 926-933
16. Hauser M.A., Amalfitano A., Kumar-Singh R., Hauschka S.D., and Chamberlain J.S. Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy. Neuromuscul Disord 7 (1997) 277-283
17. Hu H., Serra D., and Amalfitano A. Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther 10 (1999) 355-364
18. Hodges B.L., Serra D., Hu H., Begy C.A., Chamberlain J.S., and Amalfitano A. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. J Gene Med 2 (2000) 250-259
19. Everett R.S., Hodges B.L., Ding E.Y., Xu F., Serra D., and Amalfitano A. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. Hum Gene Ther 14 (2003) 1715-1726
20. Schaack J. Induction and inhibition of innate inflammatory responses by adenovirus early region proteins. Viral Immunol 18 (2005) 79-88
21. Addo M.M., Yu X.G., Rathod A., Cohen D., Eldridge R.L., Strick D., et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77 (2003) 2081-2092
22. Edwards B.H., Bansal A., Sabbaj S., Bakari J., Mulligan M.J., and Goepfert P.A. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 76 (2002) 2298-2305
23. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279 (1998) 2103-2106
24. Appay V., Dunbar P.R., Callan M., Klenerman P., Gillespie G.M.A., Papagno L., et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8 (2002) 379-385
25. Champagne P., Ogg G.S., King A.S., Knabenhans C., Ellefsen K., Nobile M., et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410 (2001) 106-111
26. Rowland-Jones S.L., Pinheiro S., Kaul R., Hansasuta P., Gillespie G., Dong T., et al. How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection?. Immunol Lett 79 (2001) 15-20